"The biomarker work we do everyday here in OBD at Genentech potentially impacts drug development as well as future patients’ care. It can’t get more rewarding and exciting than that!"
I obtained a MSc degree in Biotechnology from Jagiellonian University in Krakow, Poland and a PhD degree in Molecular and Cellular Biology from Ludwig Institute for Cancer Research in Uppsala, Sweden.
Subsequently, I was fortunate enough to join Genentech as a post-doctoral fellow in Dr. Napoleone Ferrara’s group in Research in 2005 to study a role of myeloid cells in tumorgenesis/metastasis. In 2010, I joined the Oncology Biomarker Development group as a biomarker scientist, drawn by an exciting opportunity to do biomarker research on samples from cancer patients and to make a direct impact on personalized health care. As a Biomarker lead in Cancer Immunotherapy Biomarkers, I lead identification and development of biomarkers for anti-PDL1 in patients with various types of lung cancer.
Nature. 2014 Nov 27;515(7528):563-7.
The primary focus of my group is to better understand mechanisms and biomarkers associated with response and progression to cancer immunotherapy agents being tested in clinic. We subsequently use this knowledge to identify biomarkers that could be further developed as a potential diagnostic to identify patients that may derive the most benefit from the treatment. It is an exciting process that involves linking clinical data to the biomarker data we generate from specimens obtained from cancer patients being enrolled into Genentech’s clinical trials.
Through numerous internal and external collaborations we are also focusing on the characterization of lung cancer immune environment to inform future drug development, including new treatment combination strategies.
Beyond that, as a Biomarker Lead, I am heavily involved with a number of cross-functional teams to develop and implement biomarker strategies for Genentech’s cancer immunotherapy trials.